• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Message for 2018 Cholesterol Management Guidelines Update: Time to Accept the Power of Zero.

作者信息

Nasir Khurram

机构信息

Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut; and the Center for Outcomes Research and Evaluation (CORE), Yale New Haven Health, New Haven, Connecticut.

出版信息

J Am Coll Cardiol. 2018 Dec 25;72(25):3243-3245. doi: 10.1016/j.jacc.2018.10.006.

DOI:10.1016/j.jacc.2018.10.006
PMID:30409568
Abstract
摘要

相似文献

1
Message for 2018 Cholesterol Management Guidelines Update: Time to Accept the Power of Zero.2018年胆固醇管理指南更新信息：是时候接受“零”的力量了。
J Am Coll Cardiol. 2018 Dec 25;72(25):3243-3245. doi: 10.1016/j.jacc.2018.10.006.
2
Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.通过电子束计算机断层扫描评估HMG-CoA还原酶抑制剂对冠状动脉疾病的影响。
N Engl J Med. 1998 Dec 31;339(27):1972-8. doi: 10.1056/NEJM199812313392703.
3
Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.2013 年 ACC/AHA 胆固醇指南对当代心血管实践中成年人的影响：来自 NCDR PINNACLE 注册研究的见解。
J Am Coll Cardiol. 2014 Dec 2;64(21):2183-92. doi: 10.1016/j.jacc.2014.08.041. Epub 2014 Nov 19.
4
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.他汀类药物治疗、低密度脂蛋白胆固醇、C反应蛋白与冠状动脉疾病
N Engl J Med. 2005 Jan 6;352(1):29-38. doi: 10.1056/NEJMoa042000.
5
HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.HMG辅酶A还原酶抑制剂与改善冠状动脉疾病患者的全身内皮功能有关。
Atherosclerosis. 1999 Dec;147(2):237-42. doi: 10.1016/s0021-9150(99)00189-6.
6
Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).根据美国心脏病学会/美国心脏协会胆固醇管理指南，在他汀类药物候选者中进行冠状动脉钙测试的意义：MESA（动脉粥样硬化多民族研究）。
J Am Coll Cardiol. 2015 Oct 13;66(15):1657-68. doi: 10.1016/j.jacc.2015.07.066.
7
High-intensity statin treatment for coronary heart disease.高强度他汀类药物治疗冠心病。
JAMA. 2004 Mar 3;291(9):1132-4. doi: 10.1001/jama.291.9.1132.
8
Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.近期美国国家胆固醇教育计划成人治疗小组第三次更新：调整与选择
Am J Cardiol. 2005 Aug 22;96(4A):53E-59E. doi: 10.1016/j.amjcard.2005.06.006.
9
Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy.他汀类药物（阿托伐他汀或辛伐他汀）治疗后，通过血管内超声分析测定，随访低密度脂蛋白胆固醇水平作为冠状动脉粥样硬化斑块大小变化的独立预测指标的有用性。
Am J Cardiol. 2006 Oct 1;98(7):866-70. doi: 10.1016/j.amjcard.2006.04.025. Epub 2006 Aug 4.
10
The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.他汀类药物治疗期间提高高密度脂蛋白胆固醇的有益效果取决于低密度脂蛋白胆固醇所达到的水平：对冠状动脉粥样硬化进展和心血管事件的影响。
Eur J Prev Cardiol. 2016 Mar;23(5):474-85. doi: 10.1177/2047487315572920. Epub 2015 Feb 17.

引用本文的文献

1
Implications of the 2019 American College of Cardiology/American Heart Association Primary Prevention Guidelines and potential value of the coronary artery calcium score among South Asians in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study.2019 年美国心脏病学会/美国心脏协会一级预防指南的意义，以及在美国南亚人群中冠状动脉钙评分的潜在价值：生活在美国的南亚人中动脉粥样硬化的介质（MASALA）研究。
Atherosclerosis. 2021 Oct;334:48-56. doi: 10.1016/j.atherosclerosis.2021.08.030. Epub 2021 Aug 23.
2
Temporal Trends and Interest in Coronary Artery Calcium Scoring Over Time: An Infodemiology Study.冠状动脉钙化评分随时间的时间趋势及关注度：一项信息流行病学研究
Mayo Clin Proc Innov Qual Outcomes. 2021 Apr 8;5(2):456-465. doi: 10.1016/j.mayocpiqo.2021.02.010. eCollection 2021 Apr.
3
Coronary Artery Calcium Scoring: New Insights into Clinical Interpretation-Lessons from the CAC Consortium.冠状动脉钙化评分：临床解读的新见解——来自冠状动脉钙化联盟的经验教训
Radiol Cardiothorac Imaging. 2020 Dec 17;2(6):e200281. doi: 10.1148/ryct.2020200281. eCollection 2020 Dec.
4
Coronary artery calcium testing in low-intermediate risk symptomatic patients with suspected coronary artery disease: An effective gatekeeper to further testing?低-中危症状性疑似冠心病患者的冠状动脉钙检测：是否为进一步检查的有效把关者？
PLoS One. 2020 Oct 13;15(10):e0240539. doi: 10.1371/journal.pone.0240539. eCollection 2020.
5
All-cause and cause-specific mortality in individuals with zero and minimal coronary artery calcium: A long-term, competing risk analysis in the Coronary Artery Calcium Consortium.零和微量冠状动脉钙个体的全因和死因特异性死亡率：冠状动脉钙协会的长期竞争风险分析。
Atherosclerosis. 2020 Feb;294:72-79. doi: 10.1016/j.atherosclerosis.2019.11.008. Epub 2019 Nov 16.
6
The Evolving View of Coronary Artery Calcium: A Personalized Shared Decision-Making Tool in Primary Prevention.冠状动脉钙化的演变观点：一级预防中的个性化共同决策工具。
Cardiol Res Pract. 2019 Jun 2;2019:7059806. doi: 10.1155/2019/7059806. eCollection 2019.